The quality of clinical FFP, cryoprecipitate and cryosupernatant derived from single donor apheresis procedures and random donations collected in a BAT system: assessment of the activity states of FVIII, contact activation, microvesicle content and cytokines.
In establishing the best practice and/or evaluating any new process or procedures it is essential that apart from the compliance to specification, provided by the Guidelines (i.e. AABB or UK-BTS/ NIBSC), the changes that might occur in the activation states, and other regulatory mechanisms should be considered. Of particular relevance are the changes in the levels of FVIII in relation to its carrier protein and stabiliser von Willebrand factor; the levels of contact activation and serine proteases and the level of cellular fragmentation/microvesiculation due to shear induced stress in the cellular contents of blood and the development of cytokines. This brief original report compares the above parameters for three types of FFP, cryoprecipitate and the cryosupernatant in respect to same new in house quality monitoring criteria of acceptability.
Seghatchian
M J
MJ
North London Blood Transfusion Centre, UK.
D001782:Blood Donors; D001792:Blood Platelets / Q000166:cytology* / Q000378:metabolism*; D001793:Blood Preservation; D015925:Cryopreservation; D016207:Cytokines / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D006801:Humans; D010956:Plasmapheresis; D015539:Platelet Activation; D017713:Platelet Transfusion